Market closedNon-fractional

Fate Therapeutics/FATE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Ticker

FATE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

181

FATE Metrics

BasicAdvanced
$360M
Market cap
-
P/E ratio
-$1.92
EPS
1.90
Beta
-
Dividend rate
$360M
1.9
8.693
8.473
22.451
23.954
-20.84%
-42.07%
48.378
0.84
0.84
-2.242
-95.27%
-20.66%
-45.52%
-3.49%

What the Analysts think about FATE

Analyst Ratings

Majority rating from 19 analysts.
Hold

FATE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,526.31% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.9M
18.75%
Net income
-$48M
8.84%
Profit margin
-2,526.31%
-8.34%

FATE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.83%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.46
-$0.45
-$0.47
-
Expected
-$0.59
-$0.57
-$0.52
-$0.49
-$0.48
Surprise
-8.22%
-19.28%
-13.90%
-3.83%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Fate Therapeutics stock?

Fate Therapeutics (FATE) has a market cap of $360M as of July 06, 2024.

What is the P/E ratio for Fate Therapeutics stock?

The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of July 06, 2024.

Does Fate Therapeutics stock pay dividends?

No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Fate Therapeutics dividend payment date?

Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.

What is the beta indicator for Fate Therapeutics?

Fate Therapeutics (FATE) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Fate Therapeutics stock

Buy or sell Fate Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing